Triumeq is a fixed-dose combination preparation used for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection. It consists of three active ingredients: abacavir, dolutegravir, and lamivudine. As a highly effective antiretroviral therapy (ART) medication, Triumeq is widely used in both adult and pediatric patients.

Indications for Triumeq

Primary Indications

Triumeq is indicated for the treatment of HIV-1 infection in adult patients, as well as pediatric patients aged 3 months and older with a body weight of at least 6 kg.

Through the combined action of three drugs with different mechanisms, this medication effectively inhibits viral replication, enhances immune system function, and controls the progression of the disease.

Precautions

Triumeq is not suitable for all HIV-infected individuals.

If a patient has pre-existing drug-resistant mutations associated with integrase inhibitors, or if resistance to integrase strand transfer inhibitors (INSTIs) is clinically suspected, Triumeq should not be used alone for treatment.

This is because in such cases, the dose of dolutegravir in the medication may be insufficient to effectively inhibit the virus. The treatment regimen needs to be adjusted according to the patient’s specific condition or alternative antiviral drug combinations should be selected.

Contraindications

HLA-B*5701 allele screening must be performed before using Triumeq.

Patients carrying this allele have a significantly increased risk of developing severe hypersensitivity reactions when using abacavir; therefore, this product is contraindicated in such patients.

All patients should also undergo hepatitis B virus (HBV) testing before initiating treatment. This is because patients with concurrent HBV infection may experience acute exacerbation of hepatitis after discontinuing the medication.

Specifications and Properties of Triumeq

Regular Tablets

Triumeq regular tablets are purple, biconvex, oval film-coated tablets, engraved with "572Tri" on one side.

Each tablet contains 600 mg of abacavir (as abacavir sulfate), 50 mg of dolutegravir (as dolutegravir sodium), and 300 mg of lamivudine.

This dosage form is mainly suitable for adult patients and pediatric patients with a body weight of at least 25 kg.

Oral Suspension Tablets

Triumeq PD oral suspension tablets are yellow, capsule-shaped, film-coated tablets with a strawberry cream flavor and a biconvex design, engraved with "SVWTU" on one side.

Each tablet contains 60 mg of abacavir (as abacavir sulfate), 5 mg of dolutegravir (as dolutegravir sodium), and 30 mg of lamivudine.

This dosage form is specifically designed for pediatric patients with a body weight between 6 kg and less than 25 kg. It must be dispersed in drinking water before oral administration and should not be swallowed whole directly.

Storage Methods for Triumeq

Storage Temperature

The storage temperature should be controlled between 20°C and 25°C (68°F and 77°F). Short-term temperature fluctuations within the range of 15°C to 30°C (59°F to 86°F) are permitted.

The medication should not be placed in bathrooms or cars, as the temperature and humidity in these locations may exceed the recommended range.

Storage of Oral Suspension Tablets

For oral suspension tablets, the reconstituted suspension should be administered within 30 minutes.

The bottle cap should be tightly closed immediately after each dose is taken to ensure that the remaining tablets are not affected by the environment.

All medications should be stored in a place out of the reach of children to prevent accidental ingestion.